Abrogation of antibody-induced arthritis in mice by a self-activating viridin prodrug and association with impaired neutrophil and endothelial cell function

Arthritis and Rheumatism

Volumn 60, Issue 8, 2009, Pages 2314-2324

  Stangenberg, Lars ^a   Ellson, Chris ^b   Cortez Retamozo, Virna ^a   Ortiz Lopez, Adriana ^b,c   Yuan, Hushan ^a   Blois, Joseph ^a   Smith, Ralph A ^a   Yaffe, Michael B ^b   Weissleder, Ralph ^a   Benoist, Christophe ^b,c   Mathis, Diane ^b,c   Josephson, Lee ^a   Mahmood, Umar ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; PROTEINASE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; WORTMANNIN;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BLOOD VESSEL PERMEABILITY; C57BL 6 MOUSE; CELL ACTIVATION; CELL FUNCTION; CELL INTERACTION; CELL VACUOLE; CONTROLLED STUDY; DEGRANULATION; DOSE RESPONSE; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME ACTIVITY; INFLAMMATION; JOINT DESTRUCTION; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY BURST; SLOW DRUG RELEASE;

ANDROSTADIENES; ANDROSTENES; ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; BACTERIOCINS; CELL ADHESION; CELL MEMBRANE PERMEABILITY; ENDOTHELIUM, VASCULAR; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEUTROPHILS; PRODRUGS;

EID: 68049103240     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24704     Document Type: Article

References (43)

1. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20.
2. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
3. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
4. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
5. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
6. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-9.
7. Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L, et al. Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation. Science 2000;287:1049-53.
8. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D. Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction. Science 2000;287:1046-9.
9. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B, et al. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science 2000;287:1040-6.
10. Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A, et al. A crucial role for the p110δ subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002; 196:753-63.
11. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, et al. Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science 2002;297:1031-4.
12. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C, et al. Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature 2004;431:1007-11.
13. Laffargue M, Calvez R, Finan P, Trifilieff A, Barbier M, Altruda F, et al. Phosphoinositide 3-kinase γ is an essential amplifier of mast cell function. Immunity 2002;16:441-51.
14. Camps M, Rueckle T, Ji H, Ardissone V, Rintelen F, Shaw J, et al. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005;11:936-43.
15. Randis T, Puri K, Zhou H, Diacovo T. Role of PI3Kγ and PI3Kδ in inflammatory arthritis and tissue localization of neutrophils. Eur J Immunol 2008;38:1215-24.
16. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 1993;296: 297-301.
17. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 2006;125:733-47.
18. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, Waterfield MD, et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996;16:1722-33.
19. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000;6:909-19.
20. Wiesinger D, Gubler HU, Haefliger W, Hauser D. Antiinflammatory activity of the new mould metabolite 11-desacetoxy-wortmannin and of some of its derivatives. Experientia 1974;30:135-6.
21. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001;70:535-602.
22. Yuan H, Luo J, Weissleder R, Cantley L, Josephson L. Wortmannin-C20 conjugates generate wortmannin. J Med Chem 2006;49: 740-7.
23. Blois J, Yuan H, Smith A, Pacold ME, Weissleder R, Cantley LC, et al. Slow self-activation enhances the potency of viridin prodrugs. J Med Chem 2008;51:4699-707.
24. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell 1996;87:811-22.
25. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, et al. Arthritis critically dependent on innate immune system players. Immunity 2002;16:157-68.
26. Matsumoto I, Staub A, Benoist C, Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999;286:1732-5.
27. Binstadt BA, Patel PR, Alencar H, Nigrovic PA, Lee DM, Mahmood U, et al. Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat Immunol 2006;7: 284-92.
28. Wu HJ, Sawaya H, Binstadt B, Brickelmaier M, Blasius A, Gorelik L, et al. Inflammatory arthritis can be reined in by CpG-induced DC-NK cell cross talk. J Exp Med 2007;204:1911-22.
29. Yuan H, Barnes KR, Weissleder R, Cantley L, Josephson L. Covalent reactions of wortmannin under physiological conditions. Chem Biol 2007;14:321-8.
30. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297-315.
31. Rommel C, Camps M, Ji H. PI3Kδ; and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 2007;7:191-201.
32. Lee KS, Park SJ, Kim SR, Min KH, Jin SM, Puri KD, et al. Phosphoinositide 3-kinase-δ inhibitor reduces vascular permeability in a murine model of asthma. J Allergy Clinical Immunol 2006;118:403-9.
33. Kilic E, Kilic U, Wang Y, Bassetti CL, Marti HH, Hermann DM. The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB J 2006;20:1185-7.
34. Chen M, Lam BK, Kanaoka Y, Nigrovic PA, Audoly LP, Austen KF, et al. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med 2006;203:837-42.
35. Wipke BT, Allen PM. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol 2001;167:1601-8.
36. Puri KD, Doggett TA, Douangpanya J, Hou Y, Tino WT, Wilson T, et al. Mechanisms and implications of phosphoinositide 3-kinase δ in promoting neutrophil trafficking into inflamed tissue. Blood 2004;103:3448-56.
37. Puri KD, Doggett TA, Huang CY, Douangpanya J, Hayflick JS, Turner M, et al. The role of endothelial PI3Kγ activity in neutrophil trafficking. Blood 2005;106:150-7.
38. Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994;179:1517-27.
39. Williams DL, Li C, Ha T, Ozment-Skelton T, Kalbfleisch JH, Preiszner J, et al. Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis. J Immunol 2004;172:449-56.
40. Foey A, Green P, Foxwell B, Feldmann M, Brennan F. Cytokine-stimulated T cells induce macrophage IL-10 production dependent on phosphatidylinositol 3-kinase and p70S6K: implications for rheumatoid arthritis. Arthritis Res 2002;4:64-70.
41. Jonsson H, Allen P, Peng S. Inflammatory arthritis requires FoxOa3 to prevent Fas ligand-induced neutrophil apoptosis. Nat Med 2005;11:666-71.
42. Kannan K, Ortmann RA, Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 2005;12:167-81.
43. Zask A, Kaplan J, Toral-Barza L, Hollander I, Young M, Tischler M, et al. Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy. J Med Chem 2008;51:1319-23.